Skip to main content
Premium Trial:

Request an Annual Quote

Biolog Wins $2.5M Phase II NIH SBIR Grant to Develop Tox Applications for Cell Arrays

NEW YORK, Oct. 13 (GenomeWeb News) - Biolog has won a $2.5 million phase II SBIR grant from the NIH to further develop its cellular microarray technology, the Hayward, Calif.-based company said today.

 

Specifically, the company plans to develop cell-based assays for toxicology testing, based on its Phenotype MicroArray assay platform.

 

Under the phase I portion of the grant, Biolog has already developed a number of cell assays for use with human and mouse cell lines.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.